Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: The influence of flow and volume

International Journal of Pharmaceutics

Volumn 455, Issue 1-2, 2013, Pages 213-218

  Yakubu, Sani Ibn ^a,b   Assib, Khaled H ^b   Chrystyn, Henry ^c  

^a UNIVERSITY OF MAIDUGURI   (Nigeria)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

Different volumes; Dose emission; Dry powder inhaler; Low flows

Indexed keywords

SALBUTAMOL SULFATE; TERBUTALINE SULFATE;

ANDERSEN CASCADE IMPACTOR; ARTICLE; DRY POWDER INHALER; FLOW MEASUREMENT; FLOW RATE; INHALATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; METHODOLOGY; PHARMACOLOGICAL PROCEDURES; PRESSURE; PRIORITY JOURNAL;

DIFFERENT VOLUMES; DOSE EMISSION; DRY POWDER INHALER; LOW FLOWS;

ADMINISTRATION, INHALATION; ALBUTEROL; DRY POWDER INHALERS; RHEOLOGY; TECHNOLOGY, PHARMACEUTICAL; TERBUTALINE;

EID: 84883882272     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.07.036     Document Type: Article

References (36)

1. Abdelrahim, M.E., 2010. Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions. Respir Med 104, 682-689.
2. Azouz, W., Chrystyn, H., 2012. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim. Care Respir. J. 21, 208-213.
3. Azouz, W., Chetcuti, P., Hosker, H., Saralaya, D., Chrystyn, H., 2013. Inhalation characteristics of patients when they use dry powder inhalers (DPIs). Abstract (P-052) presented at International Society of Medicines 2013. J. Aerosol Med. Pulmonary Drug Deliv. 26, A-38.
4. Borgstrom, L., Bondesson, E., Moren, E., Trofast, E., Newman, S.P., 1994. Lung deposition of budesonide inhaled via Turbuhaler. A comparison with terbutaline sulphate. Eur. Respir. J. 7, 69-73. (Pubitemid 24075127)
5. Bisgaard, H., Klug, B., Sumby, B.S., Burnell, P.K., 1998. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Respir. J. 11, 1111-1115. (Pubitemid 28281031)
6. Broeders, M., Molema, J., Vermue, N.A., Folgering, H.T.M., 2001. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur. Respir. J. 18, 780-783. (Pubitemid 33076919)
7. Broeders, M.E., Molema, J., Hop, W.C., Folgering, H.T., 2003. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J. Aerosol Med. 16, 131-141. (Pubitemid 36702667)
8. Chege, J.K., Chrystyn, H., 2000. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation. Respir. Med. 94, 51-56. (Pubitemid 30113850)
9. Chrystyn, H., 2009. Effects of device design on patient compliance: (2009) Comparing the same drug in different devices. In: Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Young, P.M. (Eds.), Respiratory Drug Delivery Europe 2009. Davis Healthcare International Publishing, pp. 105-116.
10. Chrystyn, H., Price, D., 2009. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim. Care Respir. J. 18, 243-249.
11. de Boer, A.H., Gjaltema, D., Hagedoorn, P., 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers part 2: effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int. J. Pharm. 138, 45-56. (Pubitemid 26241921)
12. Clark, A.R., Hollingworth, A.M., 1993. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J. Aerosol Med. 6, 99-110. (Pubitemid 23231366)
13. Engel, T., Scharling, B., Skovsted, B., Heing, J., 1992. Effects, side effects and plasma concentrations of Terbutaline in adult asthmatics when inhaling from a dry powder inhaler device and different inhalation flows and volumes. Br. J. Clin. Pharmacol. 33, 439-444.
14. European Pharmacopeia, 2012. Preparations for inhalation: aerodynamic assessment of fine particles. European Pharmacopoeia, 7.6th ed, http://findpdf.net/documents/european-pharmacopoeia-7-0.html [cited 18.01.13].
15. Everard, M.L., Devadason, S.G., Le Souef, P.N., 1997. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 91, 624-628. (Pubitemid 27453661)
16. Hawksworth, G.M., James, L., Chrystyn, H., 2000. Characterization of the inspiratory manoeuvre when asthmatics inhale through a Turbohaler pre- and post-counselling in a community pharmacy. Respir. Med. 94, 501-504. (Pubitemid 30353009)
17. Hill, L.S., Slater, A.L., 1998. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir. Med. 92, 105-110. (Pubitemid 28112050)
18. Hirsch, T., Peter-Kern, M., Koch, R., Leupold, W., 1997. Influence of inspiratory capacity on bronchodilation of terbutaline via Turbuhaler or pressurised metered-dose inhaler in asthmatic children: a comparison. Respir. Med. 91, 341-346. (Pubitemid 27270348)
19. Kamin, W.E., Genz, T., Roedre, S., Scheuch, G., Trammer, T., Juenemann, R., Cloes, R.M., 2002. Mass output and particle size distribution of glucocosteroids emitted from different inhalation devices depending on various inspiratory parameters. J. Aerosol Med. 15, 65-73. (Pubitemid 34327057)
20. Koskela, T., Malmstrom, K., Sairanen, U., 2000. Efficacy of salbutamol via Easyhaler® unaffected by low inspiratory flow. Respir. Med. 94, 1229-1233. (Pubitemid 32049251)
21. Laube, B.L., Janssens, H.M., de Jongh, F.H.C., Devadason, S.G., Dhand, R., Diot, P., Everard, M.L., Horvath, I., Navalesi, P., Voshaar, T., Chrystyn, H., 2011. ERS/ISAM task force consensus statement: recommendations on what the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 37, 1308-1331.
22. Malton, A., Sumby, B.S., Dandiker, Y., 1996. A comparison of in-vitro drug delivery from salbutamol Diskus and terbutaline Turbuhaler inhalers. J. Pharm. Med. 6, 35-48. (Pubitemid 27013274)
23. Mohammed, H., Roberts, D.L., Copley, M., Hammond, M., Nichols, S.C., Mitchell, J.P., 2012. Effect of sampling volume on dry powder inhaler (DPI)-emitted aerosol aerodynamic particle size distributions (APSDs) measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen eight-stage cascade impactor (ACI). AAPS Pharm. SciTech. 13, 875-882.
24. Nadarassan, D.K., Assi, K.H., Chrystyn, H., 2010. Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor. Eur. J. Pharm. Sci. 39, 348-354.
25. Newhouse, M.T., Nantel, N.P., Chambers, C.B., Pratt, B., Parry-Billings, M., 1995. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest 115, 952-956. (Pubitemid 29193660)
26. Newman, S., Moren, F., Trofast, E., Talaee, N., Clarke, S., 1991. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on deposition and efficacy. Int. J. Pharm. 74, 209-213.
27. Nielsen, K.G., Auk, I.L., Bojsen, K., Ifversen, M., Klug, B., Bisgaard, H., 1998. Clinical effect of Diskus dry powder inhaler at low and high inspiratory flow rates in asthmatic children. Eur. Respir. J. 11, 350-354. (Pubitemid 28108348)
28. Olsson, B., Borgstrom, L., Lundback, H., Svensson, M., 2013. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. J. Aerosol Med. Pulmonary Drug Deliv. 26 [Epub ahead of print].
29. Palander, A., Mattila, T., Karhu, M., Muttonen, E., 2000. In-vitro comparison of three salbutamol-containing multidose dry powder inhalers. Clin. Drug Invest. 20, 25-33.
30. Pedersen, S., Hansen, O.R., Fuglsang, G., 1990. Influence of inspiratory flow rate upon effect of a Turbuhaler. Arch. Dis. Childhood 65, 308-310. (Pubitemid 20108901)
31. Roberts, D.L., Mitchell, J.P., 2013. he effect of nonideal cascade impactor stage collection ef.cience curves on the interpretation of the size of inhaler-generated aerosols. AAPS PharmSciTech. 14, 487-509.
32. Ross, D.L., Schultz, R.K., 1996. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J. Aerosol Med. 9, 215-226. (Pubitemid 26192807)
33. Tarsin, W., Assi, K.H., Chrystyn, H., 2004. In-vitro inhalation flow rate dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J. Aerosol Med. 17, 25-32. (Pubitemid 38520670)
34. Tarsin, W.Y., Pearson, S.B., Assi, K.H., Chrystyn, H., 2006. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int. J. Pharm. 316, 131-137.
35. United States Pharmacopeia, 2012. Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. The United States pharmacopeia 35 [and] the national formulary 30, http://www.uspnf.com/uspnf/login [cited 18.01.13].
36. Van Oort, M., 1995. In vitro testing of dry powder inhalers. Aerosol Sci. Technol. 22, 364-373.